The QualityStocks Daily Wednesday, June 29th, 2022

Today's Top 3 Investment Newsletters

QualityStocks(ALNA) $0.2550 +114.29%

MarketClub Analysis(DBTX) $3.8200 +44.15%

Tiny Gems(ADTX) $0.2000 +39.76%

The QualityStocks Daily Stock List

Soleno Therapeutics (SLNO)

StockMarketWatch, MarketBeat, TradersPro, StreetInsider, TraderPower, QualityStocks, TradersPro Morning, TopPennyStockMovers, StockRockandRoll, Stock Beast, Schaeffer's, PennyStockLocks, Penny Stock 101 and Money Morning reported earlier on Soleno Therapeutics (SLNO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Soleno Therapeutics Inc. (NASDAQ: SLNO) (FRA: 6XC1) is a clinical stage biopharmaceutical firm that is engaged in the development and commercialization of new therapies for the treatment of various rare diseases.

Soleno Therapeutics is headquartered in Redwood City, California and was established on August 25, 1999. Before changing its name to Soleno Therapeutics Inc. in 2017, the firm was known as Capnia Inc.

Soleno Therapeutics is party to a collaboration agreement with Vanderbilt University that entails the discovery and development of next generation K(ATP) activators to treat rare ailments. The firm is focused on the treatment of neurobehavioral and metabolic disorders.

Soleno Therapeutics’ product candidates include an oral tablet to be ingested once a day indicated for the treatment of Prader-Willi Syndrome dubbed DCCR or Diazoxide Choline Controlled-Release tablets. The candidate is currently being assessed for its effectiveness in a phase 3 clinical development program. The firm also provides products like Serenz Nasal Relief, which is a nasal irrigator that uses carbon dioxide to wash nasal passages; NeoPIP Infant Resuscitator, which has been developed to help resuscitate infants and neonates in the clinical environment and the CoSense ETCO end-tidal carbon monoxide (ETCO) monitor. Soleno Therapeutics designed the monitor to measure end-tidal carbon monoxide to help detect fatal rates of hemolysis.

Soleno Therapeutics Inc. recently announced that they would be conducting another clinical trial to support their NDA submission for DCCR to the FDA. This, their CEO said, would ensure that the product, which has shown its potential as an effective and safe treatment option for patients with PWS, is approved for patients as swiftly as possible.

Soleno Therapeutics (SLNO), closed Wednesday's trading session at $0.1966, up 12.4071%, on 4,591,376 volume. The average volume for the last 3 months is 4.591M and the stock's 52-week low/high is $0.1302/$1.175.

Avenue Therapeutics (ATXI)

QualityStocks, StocksEarning, MarketBeat, Zacks, StreetInsider, StockMarketWatch, TradersPro, Schaeffer's, Marketbeat.com, TradersPro Morning, SmallCapVoice, PoliticsAndMyPortfolio and MarketClub Analysis reported earlier on Avenue Therapeutics (ATXI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Avenue Therapeutics Inc. (NASDAQ: ATXI) (FRA: 49Y) is a specialty pharmaceutical firm that is engaged in the acquisition, licensing, development and commercialization of products that are mainly used in the intensive/acute care hospital setting.

The firm has its headquarters in New York and was incorporated in 2015, on February 9th. It operates in the healthcare sector, under the biotech and pharma sub-industry. The company is a majority-controlled subsidiary firm of Fortress Biotech Inc., which is a biopharmaceutical firm that is also engaged in the acquisition, development and commercialization of new biotechnology and pharmaceutical products.

The company develops intravenous Tramadol, which is currently undergoing phase 3 clinical trials for the treatment of moderate to severe post-surgical pain. The synthetic dual-acting opioid works by inhibiting noradrenaline and serotonin re-uptake and blocking spinal level nociceptive impulses and could be used as an alternative for conventional opioids. The oral formulation of this candidate is marketed in the U.S. for moderate to severe pain in grown-ups. Its parenteral formulations include subcutaneous and intramuscular formulations. The drug itself is marketed in the U.S. under the Ultram trade name. Ultracet, which is a combination product of acetaminophen and tramadol, is also sold in the U.S.

The firm is pursuing regulatory approval for its IV tramadol drug formulation, after the FDA cited in their Complete Response Letter that they did not find any controls, manufacturing or chemistry issues with its candidate. If successful, the firm will introduce the drug to the market, which will increase its revenue and boost share prices as well encourage more investments into the firm.

Avenue Therapeutics (ATXI), closed Wednesday's trading session at $0.3235, up 32.0408%, on 3,561,265 volume. The average volume for the last 3 months is 3.549M and the stock's 52-week low/high is $0.20/$2.81.

Lineage Cell Therapeutics (LCTX)

BUYINS.NET, TradersPro, StockMarketWatch, MarketBeat, Wealth Insider Alert, StreetInsider and QualityStocks reported earlier on Lineage Cell Therapeutics (LCTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Lineage Cell Therapeutics Inc. (NYSE American: LCTX) (FRA: BT3) is a clinical-stage biotechnology firm that is engaged in the development and commercialization of treatments for degenerative ailments.

The firm has its headquarters in Carlsbad, California and was incorporated in 1990, on November 30th by Harold D. Waitz, Paul E. Segall, Hal Sternberg and Judith Segall. Prior to its name change in August 2019, the firm was known as BioTime Inc. It serves patients across the globe.

The company is party to a collaboration with Orbit Biomedical Ltd. Its programs are based off of two core proprietary technology platforms, namely cell and drug delivery and cell replacement. The drug delivery programs are based on its HyStem cell and drug delivery matrix technology, while its cell replacement platform creates new tissues and cells with its progenitor and pluripotent cell technologies. The majority of the company’s revenue is generated from the United States.

The enterprise’s product pipeline includes an epithelium cell replacement therapy dubbed OpRegen which is indicated for the treatment of dry age-related macular degeneration and is currently undergoing a phase 2a clinical trial. It also offers an allogeneic cancer immunotherapy known as VAC2, which is currently in a phase 1 clinical trial evaluating its effectiveness in treating non-small cell lung cancer; and an oligodendrocyte progenitor cell therapy dubbed OPC1, which is undergoing a phase 1/2a clinical trial and has been developed to treat acute spinal cord injuries.

The firm reported their 2021 second quarter operating and financial results, with its CEO noting that the firm was focused on improving outcomes for individuals with degenerative ailments. The success of their formulations will have a positive influence on its growth as well as investments into the firm.

Lineage Cell Therapeutics (LCTX), closed Wednesday's trading session at $1.61, up 12.5874%, on 1,909,700 volume. The average volume for the last 3 months is 1.908M and the stock's 52-week low/high is $1.10/$2.9873.

Allena Pharmaceuticals (ALNA)

MarketBeat, StockMarketWatch, QualityStocks, StocksEarning, Kiplinger Today, StreetInsider, InvestorPlace, Wall Street Mover, PoliticsAndMyPortfolio, MarketClub Analysis and BUYINS.NET reported earlier on Allena Pharmaceuticals (ALNA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Allena Pharmaceuticals Inc. (NASDAQ: ALNA) (FRA: 0PJ) is a late-stage clinical biopharmaceutical firm that is focused on developing and commercializing oral enzyme therapies for treating kidney disorders as well as severe and rare metabolic disorders.

The firm has its headquarters in Newton, Massachusetts and was incorporated in 2011, on June 24th by Alexey L. Margolin and Robert Gallotto. It operates as part of the health care sector, under the biotech and pharma sub-industry and serves consumers in the U.S.

The company is focused on treating complex metabolic conditions that can bring about costly and significant health complications. Its objective is to decrease the burden of toxic metabolites like uric acid and oxalate, which can build up and cause complications like gout and hyperuricemia or kidney stones and hyperoxaluria respectively. The company’s proprietary technological approach enables the formulation and oral delivery of stable and non-absorbed enzymes in sufficient doses for the gastrointestinal tract.

The enterprise’s product pipeline comprises of a urate degrading enzyme dubbed ALLN-346, developed for patients suffering from moderate to severe chronic kidney ailments and hyperuricemia; and an oral enzyme therapeutic known as reloxaliase that is currently undergoing a phase 3 trial evaluating its efficacy in treating hyperoxaluria, which is a metabolic disorder commonly linked to kidney stones in grown-ups.

The company is focused on the advancement of its oral enzyme product candidates through clinical development for patients with hyperoxaluria. The treatment’s approval by the FDA and its entrance to the market will help meet unmet medical needs, which will be beneficial to patients and bring in more investments into the firm.

Allena Pharmaceuticals (ALNA), closed Wednesday's trading session at $0.255, up 114.2857%, on 576,064,289 volume. The average volume for the last 3 months is 576.064M and the stock's 52-week low/high is $0.0683/$1.45.

Kaleyra Inc. (KLR)

MarketBeat, Wealth Insider Alert, StreetInsider and StockMarketWatch reported earlier on Kaleyra Inc. (KLR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Kaleyra Inc. (NYSE: KLR) (FRA: 3YK) is a software firm that is engaged in the provision of mobile communication services.

The firm has its headquarters in Milan, Italy and was incorporated in 1999 by Dario Leopoldo Calogero. It operates as part of the software-application industry, under the technology sector. The firm was formed as a result of a merger between Ubiquity and Solutions Infini. It serves consumers around the globe, with a primary focus on South America, Europe, the United States, India and Italy.The firm generates most of its revenues from Italy.

The enterprise has developed a proprietary platform which, in conjunction with its application programming interface, helps manage multi-channel integrated communication services on an international scale, comprising of chatbots, voice services, instant messaging, e-mail, push notifications and messages. Campaign Registry Inc., the company’s subsidiary, is a systems initiative to decrease spam by collecting robotically-driven campaign data, processing and sharing that data with the messaging ecosystem and mobile operators. The enterprise’s technology allows partners to manage billions of messages monthly with 1,600 operator connections in 190 nations. It serves software firms, OTTs (over the tops), e-commerce players, financial institutions, logistics enablers, healthcare providers, retailers and other organizations.

The company’s latest financial results show significant increases in its revenues and profit, with its CEO noting that they remained focused on fostering growth through strong profitability metrics and healthy revenue streams. This will help create value for its shareholders and open the company up to numerous opportunities.

Kaleyra Inc. (KLR), closed Wednesday's trading session at $2.09, off by 0.947867%, on 360,664 volume. The average volume for the last 3 months is 360,655 and the stock's 52-week low/high is $2.03/$14.23.

Femasys Inc. (FEMY)

MarketBeat reported earlier on Femasys Inc. (FEMY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Femasys Inc. (NASDAQ: FEMY) is a biomedical firm that is focused on the research, development and manufacture of next-generation advancements and new solutions which offer considerable clinical impact to address areas which are severely underserved.

The firm has its headquarters in Suwanee, Georgia and was incorporated in 2004 by Kathy-Lee Sepsick. It operates as part of the medical instruments and supplies industry, under the healthcare sector. The firm serves consumers around the world, with a focus on the U.S.

The company is primarily focused on transforming women’s healthcare. Its objectives are to offer women with minimally invasive, non-surgical product technologies, improve patient care and overall health economics.

The enterprise’s product pipeline is comprised of FemEMB, which has been developed for endometrial sampling for detecting uterine cancer. It also develops a biopsy device dubbed FemCerv, for endocervical curettage; a saline-air device known as FemVue; and an artificial insemination solution known as FemaSeed, which features intrauterine directional delivery. In addition to this, the enterprise develops permanent birth control solutions, including FemChec and FemBloc. Its FemBloc system features dual intrauterine directional delivery, which targets fallopian tubes with a degradable biopolymer. The enterprise provides its infertility products to reproductive endocrinologists, women's healthcare provider organizations, related healthcare professionals and obstetrics-gynecological physicians.

The firm remains focused on broadening its solutions to improve the continuum of healthcare options for women. This not only benefits patients in need of their solutions but will also encourage more investments into the firm, which will positively influence its growth.

Femasys Inc. (FEMY), closed Wednesday's trading session at $2.76, up 7.393%, on 665,411 volume. The average volume for the last 3 months is 665,411 and the stock's 52-week low/high is $1.26/$10.79.

Avita Medical (RCEL)

MarketBeat, The Street, StreetInsider and StockMarketWatch reported earlier on Avita Medical (RCEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Avita Medical Inc. (NASDAQ: RCEL) (OTC: AVHHL) (ASX: AVH) (FRA: 51KB) is a commercial-stage regenerative tissue firm that is focused on developing and commercializing therapies to help address the unmet needs of patients with chronic wounds, burns and aesthetics indications.

The firm has its headquarters in Valencia, California and was incorporated in 2000. Prior to its name change in December 2020, the firm was known as Avita Therapeutics Inc. It operates as part of the medical devices industry, under the healthcare sector. The firm serves consumers around the globe, with a focus on those in the United States, the United Kingdom and Australia.

The company is party to a research collaboration with Houston Methodist Research Institute, which involves exploring the reversal of cellular aging on a molecular level, via a new cell suspension delivery system. It is also party to a research collaboration with the School of Medicine at the University of Colorado, which entails the establishment of a pre-clinical proof-of-concept for a spray-on treatment of cells that are genetically corrected.

The enterprise’s lead product candidate is a device known as the Recell system, which allows healthcare professionals to develop a suspension of spray-on skin cells through the use of a small sample of a patient’s skin. These cells are used to help treat acute thermal burns in patients aged 18 and above.

The firm recently announced its latest financial results, which show substantial increases in its revenues. Its remains focused on driving revenue growth, which will help create value for its shareholders while also boosting its overall growth.

Avita Medical (RCEL), closed Wednesday's trading session at $5.05, off by 3.2567%, on 99,873 volume. The average volume for the last 3 months is 91,566 and the stock's 52-week low/high is $4.57/$21.21.

TCR2 Therapeutics (TCRR)

StreetInsider, MarketBeat, StockMarketWatch, Trades Of The Day and MarketClub Analysis reported earlier on TCR2 Therapeutics (TCRR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

TCR2 Therapeutics Inc. (NASDAQ: TCRR) (FRA: 2K7) is a clinical-stage immunotherapy firm that is engaged in the development of new T cell receptor therapies for individuals suffering from different cancers.

The firm has its headquarters in Cambridge, Massachusetts and was incorporated in 2015, on May 29th by Patrick A. Baeuerle. Prior to its name change in November 2016, the firm was known as TCR2 Inc. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers in the United States.

The company’s therapies are developed by powering the TCR (T cell receptor) with its first-in-class proprietary TRuC-T cells (TCR Fusion Construct T cells). It is also involved in research and collaboration agreements with industry partners and academic labs in the field of process development, gene editing, cell therapy and T-cell immunology.

The enterprise’s product pipeline is comprised of a fratricide resistant CD70 which targets TRuC-T cells known as TC-520, which has been developed to treat renal cell carcinoma; and a mesothelin-targeted TRuC-T cell dubbed TC-510, which has concluded preclinical trials evaluating its effectiveness in treating solid tumors. It also develops monoTRuC-T cells which target mesothelin-positive solid tumors dubbed gavo-cel, which is undergoing phase I clinical trials evaluating its effectiveness in treating cholangiocarcinoma, malignant peritoneal/pleuralmesothelioma, ovarian cancer and non-small cell lung cancer.

The company recently appointed a new CFO who has extensive finance and operations experience in the biotechnology industry. This addition strengthens the company to meet any challenges while also maximizing value for its stakeholders.

TCR2 Therapeutics (TCRR), closed Wednesday's trading session at $2.94, up 1.0309%, on 822,146 volume. The average volume for the last 3 months is 822,146 and the stock's 52-week low/high is $2.065/$19.03.

The9 Limited (NCTY)

Wall Street Resources, StockMarketWatch, BUYINS.NET, China Vesting, TradersPro, SmarTrend Newsletters, TopPennyStockMovers, The Street, StreetInsider, CRWEFinance, OTCtipReporter, InvestorPlace, Investing Futures, INO.com Market Report, Faisam Trader, DrStockPick, Penny Pick Finders, CRWEPicks, Planet Penny Stocks, Buzz Stocks, CRWEWallStreet, PennyOmega, PennyStockProphet, BestOtc, PennyToBuck, Zacks, Profitable Trader Authority, Schaeffer's, StockHotTips, StockOnion, StockOodles, Street Insider, TraderPower, Trading Markets, Wealth Insider Alert and PennyStockScholar reported earlier on The9 Limited (NCTY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The9 Limited (NASDAQ: NCTY) (FRA: FZKA) is an internet firm that is primarily focused on the internet game business but is transitioning into the cryptocurrency mining business.

The firm has its headquarters in Shanghai, the People’s Republic of China and was incorporated in 1999, on December 22nd by Jun Zhu. Prior to its name change in February 2004, the firm was known as GameNow.net Ltd. It operates as part of the electronic gaming and multimedia industry, under the communication services sector. The firm serves consumers in China, Hong Kong, Singapore and the United States.

The company’s primary businesses are focused on operating and developing computer games and mobile phones. It operates through its subsidiaries in the Greater China and other areas geographical segments.

The enterprise provides online games, which include television games, mobile games, social games, web games, MMOFPSs (massively multiplayer online first-person shooter games) and MMORPGs (massively multiplayer online role playing games). Its main products include CrossFire, The World of Kings, the Legend of Immortals and others. The enterprise is also engaged in mining of cryptocurrency as well as in the development of NFTSTAR, an NFT trading and community platform that offers users interactive, trade and purchase activities.

The company recently entered into an agreement to purchase a blockchain computing center through its NBTC Ltd subsidiary. This move will enable the company to expand its operational capacity, which will positively influence its revenues and investments. This will also open the company up to new growth opportunities and help bolster its growth.

The9 Limited (NCTY), closed Wednesday's trading session at $2.13, off by 0.46729%, on 2,091,799 volume. The average volume for the last 3 months is 2.092M and the stock's 52-week low/high is $1.14/$18.41.

Industrial Nanotech Inc. (INTK)

Stock Guru, UndiscoveredEquities, OTCPicks, The Cervelle Group, Industrial Nanotech, QualityStocks, PennyTrader Publisher, Stock Stars, TheStockWizards.net, Stocks That Move, MadPennyStocks, PennyInvest, Greenbackers, FeedBlitz, CoolPennyStocks, HotOTC, PennyStockVille, BullRally, SmallCapVoice, WiseAlerts, StockEgg, StockGuru, StockRich, The Cevelle Group and Pumps and Dumps reported earlier on Industrial Nanotech Inc. (INTK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Industrial Nanotech (OTC: INTK), a global nanoscience solutions and research leader, today announced resolution of a major recent supply chain issue. “One of our top selling products for major industrial customers is EPX-H2O. This is what companies like Exxon and Nestle and industries like the railroad industry and chemical manufacturing use,” said Stuart Burchill, CEO of Industrial Nanotech. “Very recently we were informed that a key resin used in EPX-H2O was not available in inventory and would no longer be manufactured and we had to halt production. This impacted Q2 2022 revenue and, as required, we promptly informed our shareholders of this material event. Simultaneously, we were informed that there was an offset from the same manufacturer… a new resin… that might work as a replacement. We began testing it. I returned from Spain late last night and personally saw the results today at our company laboratory this morning. As CTO, I am required to sign off on all formulations. I signed off on the new EPX-H2O formula. It is excellent.”

To view the full press release, visit https://ibn.fm/dYYqP

About Industrial Nanotech Inc.

Industrial Nanotech is a global nanoscience solution and product development leader. For more information, visit the company’s website at www.Industrial-Nanotech.com.

Industrial Nanotech Inc. (INTK), closed Wednesday's trading session at $0.0099, off by 1%, on 8,867,753 volume. The average volume for the last 3 months is 8.868M and the stock's 52-week low/high is $0.000093/$0.048651.

Gratomic Inc. (CBULF)

QualityStocks and equities Canada reported earlier on Gratomic Inc. (CBULF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Gratomic (TSX.V: GRAT) (OTCQX: CBULF) (FSE: CB82), a multinational company focused on becoming a leading global graphite supplier, today announced that it has successfully completed the first stage of its Diamond Drilling (“DD”) program at its Aukam Graphite Project in Namibia. According to the update, 16 holes, totaling 1,218.85 meters, were drilled during this first stage of the program, which concluded on June 24, 2022. Hole depths varied from 42 to 141.1 m, with all holes intercepting graphite veins, as expected by the company. Drill core samples were sent to laboratories in Namibia and South Africa, and assay results are expected within 30 days. The results will enable completion of geological modelling of the drilled mineralization and quantified and new drill targets to be defined and pursued. In addition, the company has initiated a near-surface bench excavation program at the region in order to unveil additional mineralization, which was not previously accessible due to poor access conditions in the upper areas of the mountain. The program will work to recover eventual mineralization from this section and provide proper surfaces to accommodate drilling rigs for a second planned DD program, aiming to intercept additional veins.

To view the full press release, visit https://ibn.fm/HHX7h

About Gratomic Inc.

Gratomic is a multinational company with projects in Namibia, Brazil and Canada. The company is focused on becoming a leading global graphite supplier and aims to secure a strong position in the electric vehicle (“EV”) battery supply chain. With the continued development of its flagship Aukam project and further exploration on the company's Capim Grosso property, Gratomic sets itself apart by seeking out unique top-quality assets around the world. True to its roots, the company will continue to explore graphite opportunities displaying potential for development. The company ranked third place in the top 10 preforming mining stocks on the 2022 TSX Venture 50(TM). Large quantities of high-quality vein graphite have been shipped for testing to confirm its viability as an anode material. Gratomic is confident that the test results will provide a unique competitive advantage in its desired target markets. The company will continue to update the public on the status of these tests and will provide results as soon as they become available. The company has formed a collaboration agreement with Forge Nano. With its patented Atomic Layer Deposition (“ALD”) coating, this cooperation with Forge Nano is a key element to support Gratomic’s strategies towards the value-added phases of production of graphite for anode applications, namely micronization, spheronization and coating, making Gratomic graphite a preferred choice for use in lithium-ion batteries. For more information about the company, visit www.Gratomic.ca.

Gratomic Inc. (CBULF), closed Wednesday's trading session at $0.3008, off by 1.1177%, on 2,904 volume. The average volume for the last 3 months is 2,904 and the stock's 52-week low/high is $0.29/$1.40.

Marathon Digital Holdings Inc. (MARA)

InvestorPlace, MarketClub Analysis, StockMarketWatch, Schaeffer's, MarketBeat, QualityStocks, TradersPro, BUYINS.NET, StocksEarning, Lebed.biz, The Online Investor, Trades Of The Day, Daily Trade Alert, Marketbeat.com, The Street, TraderPower, Wall Street Mover, PoliticsAndMyPortfolio, TopPennyStockMovers, Kiplinger Today, Wealth Insider Alert, StreetAuthority Daily, FeedBlitz, Barchart, StreetInsider, DreamTeamNetwork, Promotion Stock Secrets, InvestorsUnderground, AllPennyStocks, StockOodles, Stock Beast, RedChip, Stock Analyzer and Street Insider reported earlier on Marathon Digital Holdings Inc. (MARA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Marathon Digital Holdings (NASDAQ: MARA), a leader in supporting and securing the bitcoin ecosystem, has disclosed that, as a result of a storm that passed through Hardin, Montana, earlier this month, the company’s mining operations in the region are currently without power and likely to remain offline until the damaged power generating facility can be repaired. Based on the latest inspection reports, Marathon’s Montana-based miners may have sufficient power to come back online in a reduced capacity as early as the first week of July. “The severe storm in Montana unexpectedly decreased our hash rate in June and presented us with a new challenge that we are actively working to overcome,” said Fred Thiel, Marathon’s chairman and CEO. “Bringing miners fully back online will take time, and we are committed to doing everything we can to rebuild our hash rate and to improve our bitcoin production. As part of that process, we have redirected our active miners, which represent approximately 0.6 exahash, to point towards a third-party mining pool, so that we can improve our probability of earning bitcoin while we work to bring the Hardin miners back online. Separate from this event, construction and installations in Texas have continued as scheduled, and given the current macro environment, our pipeline of potential new hosting arrangements remains strong. We appreciate the continued support of our shareholders as we work through this process.”

To view the full press release, visit https://ibn.fm/D3z13

About Marathon Digital Holdings Inc.

Marathon is a digital asset technology company that focuses on supporting and securing the bitcoin ecosystem. The company is currently in the process of becoming one of the largest and most sustainably powered bitcoin mining operations in North America, while remaining asset light. For more information about the company, visit www.MarathonDH.com.

Marathon Digital Holdings Inc. (MARA), closed Wednesday's trading session at $5.8, off by 9.7978%, on 12,163,876 volume. The average volume for the last 3 months is 12.164M and the stock's 52-week low/high is $5.65/$83.45.

The QualityStocks Company Corner

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

A duo of bipartisan congressmen is seeking support for an upcoming bill that would increase military veterans’ access to medical cannabis. Although studies have found that medical cannabis can be effective at helping veterans deal with chronic pain, insomnia, anxiety, depression and even post-traumatic stress disorder (PTSD), federal policy makes it extremely difficult for veterans to access legal cannabis. Democratic Rep. Earl Blumenauer and Republican Rep. Brian Mast are hoping to change this through their Veterans Equal Access Act. The bill would grant healthcare practitioners at the U.S. Department of Veterans’ Affairs (VA) permission to recommend medical cannabis to patients in states with legal cannabis markets. The two congressmen, cochairs of the Congressional Cannabis Caucus, also shared a letter to other House offices asking those officials to support their bill because it would ensure that veterans had equal access to state-legal medical cannabis. The letter stated that while most state-legal medical cannabis programs will allow patients with a recommendation from a medical provider to enroll, VA policy bars Veteran Affairs doctors and care providers from taking part in medical cannabis programs, including helping veterans fill requisite forms. It is unfortunate that veterans seem to be getting the short end of the stick when it comes to accessing medical marijuana while they deserve the best after serving their nation with utmost dedication. Modifying the discriminatory regulations would allow those who live in states where home grows are allowed to also grow their own cannabis, perhaps even using micro gardens such as those sold by Advanced Container Technologies Inc. (OTC: ACTX).

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Wednesday's trading session at $0.8, up 5.111%, on 739 volume. The average volume for the last 3 months is 739 and the stock's 52-week low/high is $0.54/$3.20.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Traditionally, brain tumors are diagnosed by computer topography scans (CT), magnetic resonance imaging (MRI) or a neurologic exam. However, researchers from the Karl Landsteiner University for Health Sciences (KL Krems) have now discovered a more precise and accurate way of diagnosing brain cancer by using artificial intelligence (AI) combined with physiological imaging. The researchers  used several multiclass machine learning techniques to study data sourced from MRIs and classified different brain tumors. They then compared the results produced through machine learning with classifications that were made by human specialists. Although the experts were better at specificity and sensitivity, the researchers discovered that the AI was superior in terms of precision, accuracy and spotting misclassification. As some teams focus on improving brain cancer diagnosis, others at companies such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are looking to find new treatments that will improve patient outcomes. The convergence of these different efforts bodes well for the future of cancer care across the globe.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday's trading session at $0.2749, up 4.5645%, on 1,042,782 volume. The average volume for the last 3 months is 1.042M and the stock's 52-week low/high is $0.2453/$2.68.

Recent News

SPYR Inc. (OTCQB: SPYR)

The QualityStocks Daily Newsletter would like to spotlight SPYR Inc. (OTCQB: SPYR).

SPYR (OTCQB: SPYR), dba SPYR Technologies, a diversified technology company developing products and leveraging the Internet of Things (“Iot”) for large-scale applications and industries, has released an update regarding GeoTraq, its recent acquisition. The update comes from GeoTraq chief technology officer Pierre Parent, who noted that the GeoTraq team is “elated” to be part of SPYR and what that means in its ability to develop technology and use the IoT in truly massive, industry-altering ways. GeoTraq develops and manufactures self-contained and ultra-small Mobile IoT modules for asset tracking, location-based services, and sensor modules for remote monitoring. According to the announcement, the modules are plug-and-play and include turnkey connectivity to cloud services via GeoTraq's proprietary cloud-based “WebTraq” platform. “GeoTraq’s Tracker module, which pinpoints the geo-location using cell-tower triangulation, is currently in the later stages of development and has already gained PTCRB certification and is FCC compliant,” said GeoTraq chief technology officer Pierre Parent in the press release. “GeoTraq is targeting to ship production units in Q1 2023. Right behind that will be Sensor module, which in addition to geo-location will provide remote sensor monitoring to GeoTraq’s suite of turnkey solutions. The sensor modules are being targeted for Q3 2023 release. Both devices are all-in-one turnkey solutions. They will come with built-in cellular connectivity that can be activated right outside of the box as well as access to GeoTraq’s cloud-based proprietary web portal, WebTraq. To be clear, we are working diligently to roll out a diversified suite of blue-collar IoT problem solvers with the ability to service a seemingly infinite array of applications. There is no celling on our expectations.” To view the full press release, visit https://ibn.fm/eJOIC

SPYR Inc. (OTCQB: SPYR), dba SPYR Technologies, is a technology company which, through its Applied MagiX Inc. subsidiary, develops and resells Apple®-ecosystem-compatible products with an emphasis on the growing, multibillion-dollar Internet of Things (IoT) Smart Home and Connected Car markets.

SPYR continues to identify and target acquisitions with an aim of growing its footprint in the industry and expanding the products it offers consumers, including companies developing artificial intelligence and smart-technology products. In 2020, SPYR acquired Applied MagiX Inc., a registered Apple developer and reseller of Apple ecosystem compatible products with an emphasis on the smart home market, as a wholly owned subsidiary. Applied MagiX operates in the IoT market and, more specifically, the segment of the market related to the development, manufacture and sale of devices and accessories specifically built on Apple’s HomeKit® framework. These products work within the Apple HomeKit ecosystem and are exclusive to the Apple market and its consumers.

Initially, while working to develop, manufacture and sell its own line of branded products, Applied MagiX will be sourcing HomeKit products and accessories from worldwide manufacturers, vetting and selecting best-of-breed products, selling them directly to consumers and supporting them. The company focuses on Apple consumers – a target market with higher disposable income and a demonstrated willingness to pay a premium for quality products. On average, Apple product users spend roughly twice as much on technology as other smartphone users. Those who purchase smart home products spend more than $3,000 on average.

By creating smart hardware and software solutions exclusively for Apple consumers, SPYR addresses a problem faced by that market – having few “smart” devices that integrate with Apple’s HomeKit, despite being the most affluent and loyal consumers of tech products.

Products

The company’s Applied MagiX subsidiary offers multiple product lines to its target markets. First, the subsidiary is a reseller of third-party manufactured Apple HomeKit and Apple CarPlay compatible products. HomeKit comes pre-installed on every new iPhone, while the CarPlay platform is licensed by all major auto manufacturers. Applied MagiX identifies white label products, applies the company’s branding, improves the software and sells these improved products to consumers. Finally, Applied MagiX is developing its own proprietary line of smart home and connected car products, including Apple-compatible home cameras, sensors and alarms, as well as additional Apple-compatible smart car products in the iOS ecosystem.

Among the subsidiary’s products sold to consumers are:

  • The MagixDrive Wireless CarPlay adapter, which allows users to access CarPlay wirelessly using their iPhones
  • The HomeKit Secure Video Camera with iCloud Storage
  • The Multipurpose Sensor with Alarm
  • The Environment and Motion Sensor
  • The Window and Door Contact Sensor

Market Outlook

According to Statista, the global smart home market is expected to generate revenue of more than $104 billion in 2021. The market is forecast to hit more than $187 billion in revenue by 2025, recording a CAGR of 15.75 percent.

The number of active households in the worldwide smart home market is expected to reach nearly 500 million by 2025. Household penetration is just over 12 percent in 2021 and is projected to nearly double by 2025 to more than 22 percent.

Allied Market Research valued the global connected car market at more than $63 billion in 2019 and projected a CAGR of 17.1 percent, which would push revenue to more than $225 billion by 2027. Allied identified rising consumer demand for connectivity solutions, surging need for constant connectivity, increasing dependency on technology and an upsurge in tech-savvy population as key factors driving the projected growth of the connected car market.

Management Team

James R. Thompson is the CEO, President and General Counsel of SPYR. Over the past 28 years, Mr. Thompson has deftly managed a colorful spectrum of legal clients and situations. In the process, he has helped many companies – both large and small – thrive. Now he welcomes the challenge to take the company and his career in an entirely new direction. A native of Philadelphia, he holds a J.D. from Rutgers University and a Bachelor of Science from the University of Denver.

Jennifer Duettra is the Executive Vice President of SPYR. She brings a great deal of knowledge in mobile gaming and pop culture to the company. She is an attorney and was thrilled by the prospect to combine her law experience with a chance to be creative. She is a native of Colorado and received her Bachelor of Arts in Political Science and Speech Communication from Colorado State University. She holds a J.D. from Harvard University.

Trang Nguyen is the CFO of SPYR. From 2019 to 2020, she served as the Financial Reporting Manager for Del Taco, where she was responsible for the preparation and filing of periodic financial reports with the U.S. Securities and Exchange Commission. From 2016 through 2019, Ms. Nguyen was Accounting Manager for Pinnacle Tax Accounting in Los Angeles, California. She was a part of Ernst & Young’s audit team in Los Angeles from 2006 to 2008, leading engagements on interim and year-end ad SOX 404 auditing procedures for major enterprise accounts. Ms. Nguyen holds a Bachelor of Art, Business Economics (Minor in Accounting) from the University of California, Los Angeles. She is a certified public accountant with an inactive license.

Dr. Harald Zink is the CEO, Founder and Chief Product Architect of SPYR subsidiary Applied MagiX. Prior to founding Applied MagiX, he was Director of Technologies and later Vice President of Technologies at Sarkissian Productions in Los Angeles. He also served as Director of Technologies at SMZ Technologies and, for more than 17 years, as Macintosh Technology Consultant to The Walt Disney Studios in Burbank, California. He speaks five languages and holds degrees from the University of California, Riverside.

Kelly Clark is the COO of Applied MagiX. Before joining the subsidiary, he worked as Vice President of Sales Operations at TruClear Global. Prior to that, Mr. Clark was Senior Director of Program Management at Pacific Group Ventures and Operations Manager at Barco. He has also held operations management positions at Deluxe Digital Studios and Sony Pictures Entertainment. Mr. Clark holds a bachelor’s degree in international business from the University of Southern California.

SPYR Inc. (OTCQB: SPYR), closed Wednesday's trading session at $0.022445, up 6.8047%, on 701,846 volume. The average volume for the last 3 months is 701,846 and the stock's 52-week low/high is $0.018/$0.09935.

Recent News

Sycamore Entertainment Group Inc. (OTC: SEGI)

The QualityStocks Daily Newsletter would like to spotlight Sycamore Entertainment Group Inc. (OTC: SEGI).

  • Sycamore Entertainment Group Inc., through subsidiary SEGI.TV, offers a streaming experience built on the pillars of equality, sustainability and community
  • SEGI.TV is scheduled to reach 100 million U.S. household televisions and 200 million mobile devices through Roku, Amazon Fire TV, Apple TV, Samsung Smart TV and others
  • Sycamore has entered sponsorship agreements for multiple motorsports events in an effort to connect with global influencers and build brand awareness
  • Ad-supported video on demand revenues are predicted to more than double between 2018 and 2024 to reach $56 billion across 138 countries

Sycamore Entertainment Group (OTC: SEGI) is a diversified entertainment company specializing in the acquisition, marketing and worldwide distribution of quality finished feature-length motion pictures.

Sycamore Entertainment Group Inc. (OTC: SEGI) is a diversified entertainment company specializing in the acquisition, marketing and worldwide distribution of quality finished feature-length motion pictures.

Through wholly owned subsidiary SEGI.TV, the company offers a streaming experience built on the pillars of equality, sustainability and community. SEGI.TV taps into the changing cultural environment, offering movies and television programming for a diverse audience – all without a subscription fee.

SEGI.TV

Launched in late 2020, SEGI.TV is scheduled to reach 100 million U.S. household televisions and 200 million mobile devices through Roku, Amazon Fire TV, Apple TV, Samsung Smart TV and others. The OTT streaming network operates via an ad-supported video on demand (AVOD) model, allowing Sycamore to control revenue growth by negotiating rates with advertisers as its userbase continues to expand.

The company expects this AVOD model to help SEGI.TV more efficiently grow its market share while avoiding direct competition with subscription service players such as Netflix and Hulu. Other industry players who have leveraged and grown through the ad-based revenue model include Tubi (33 million monthly users, acquired by Fox), YouTube (2 billion monthly users, acquired by Google) and Pluto TV (28 million monthly users, acquired by NBC/Viacom).

SEGI.TV lives up to its brand promise of inclusion, equality and community by:

Attracting Original/Hard-to-Find Content

SEGI.TV features uplifting content aimed at helping its users tap into the changing cultural environment, including movies, TV and sporting events, and the company continues to seek-out new and engaging programming.

On March 19, 2022, SEGI.TV streamed the long-awaited grudge match between Hafthor Bjornsson and Eddie Hall, former World’s Strongest Men. Deemed ‘The Heaviest Boxing Match in History’, the bout was available to watch in just two clicks for free, without any time-specific trials, paywalled content or sneaky subscriptions.

In speaking about the match, Sycamore CEO Edward Sylvan stated, “With live streaming sports revenues expected to quadruple by 2028, we at SEGI.TV are uniquely positioned to capitalize on this new ad supported model.”

Making Inroads with New Users

As consumers continue to shift away from traditional cable and satellite toward OTT streaming, existing options are divided into two primary categories – ad-supported and premium. While industry giants like Netflix, Disney and Apple target customers with non-ad-supported options, SEGI.TV’s AVOD model positions it as a solid alternative for individuals who are reluctant to commit to a subscription-based platform.

Increasing Viewership through Branding and Awareness

Sycamore has entered sponsorship agreements for multiple motorsports events in an effort to connect with global influencers and build brand awareness.

  • SEGI.TV sponsored the No. 10 Dallara-Honda of Alex Palou when he took the checkered flag, winning the Honda Indy Grand Prix of Alabama at Barber Motorsports Park.
  • SEGI.TV sponsored the No. 50 car of Floyd Mayweather’s TMT Racing for NASCAR’s Coca-Cola 600 at Charlotte Motor Speedway.
  • SEGI.TV sponsored the No. 99 SEGI.TV GMC HUMMER EV.R in the Extreme E all-electric global racing series, which focuses on bringing awareness to environmental and equality issues worldwide.
  • SEGI.TV has the North American broadcast right to the all-electric eSkootr Championship

Market Opportunity

The gradual move away from traditional cable and satellite TV subscriptions in the U.S. and around the world has created an opportunity for streaming companies to capitalize. According to data from Statista, the number of pay TV households in the U.S. declined from a peak of 100.5 million in 2014 to roughly 73 million in 2021. Likewise, pay TV revenue in the U.S. decreased from $104 billion in 2015 to $74 billion in 2021.

The loss for cable and satellite providers has corresponded with a boom for video-on-demand services. Subscription video-on-demand (SVOD) revenue in the U.S. reached $25 billion in 2021. According to Digital TV Research, AVOD revenues are predicted to more than double between 2018 and 2024 to reach $56 billion across 138 countries. Even SVOD mainstay Netflix is exploring AVOD as a way to combat declining subscription numbers.

As Sycamore continues to expand SEGI.TV with new, unique and eventually premium content, it is uniquely positioned to benefit from this industry trend. Through its FAST (Free Ad-Supported TV) channels, SEGI.TV positions Sycamore as one of only a handful of publicly traded, pure play companies operating in the space.

In an October 2021 report, Variety called FAST “the latest avenue for established media and entertainment companies,” and recent moves by entertainment mainstays support this notion. In April 2022, Amazon rebranded its FAST-focused AVOD service to Amazon Freevee and highlighted the rapid growth of the platform, which has tripled its monthly active users.

“Advertising video-on-demand (AVOD) and free ad-supported TV (FAST) channels are the biggest winners of the Streaming Wars, we believe, because ‘free’ always has the largest TAM (total addressable market),” Laura Martin, an analyst with equity research firm Needham, said in a recent note to clients.

Management Team

Edward Sylvan is the CEO and Co-Founder of Sycamore. He has more than 30 years’ experience in the financial service and banking industry. His banking expertise helped cultivate more than 20 years of entertainment industry relationships.

Terry Sylvan is the company’s CMO and Co-Founder. He brings to Sycamore more than 25 years of marketing and advertising experience, from global brand assignments to film marketing.

Sycamore Entertainment Group Inc. (OTC: SEGI), closed Wednesday's trading session at $0.0065, up 3.1746%, on 2,275,453 volume. The average volume for the last 3 months is 2.275M and the stock's 52-week low/high is $0.0042/$0.0495.

Recent News

Home Bistro Inc. (OTC: HBIS)

The QualityStocks Daily Newsletter would like to spotlight Home Bistro Inc. (OTC: HBIS).

  • The company’s latest financial report shows a record revenue increase of 127%
  • Company anticipates continued record top-line growth
  • HBIS is making significant strides in efforts to increase its gross profit margin, decrease operating expenses to close the gap to profitability; positive earnings are expected in 2023

The market for online meal delivery is booming, as evidenced by triple-digit revenue growth reported by Home Bistro (OTC: HBIS), a leading online meal-delivery platform that offers exclusive celebrity chef-inspired, gourmet and lifestyle ready-made meals. The company’s latest financial report shows a record revenue increase of 127% over the same period the year before (https://ibn.fm/FqHzP).

Home Bistro Inc. (OTC: HBIS) is a Miami-based company engaged in the business of providing prepackaged and prepared meals to consumers. The company has created the next generation of prepared meal delivery – Ready-Made Gourmet Meal Delivery 3.0.

Home Bistro addresses the three major problems facing the prepared food delivery market: poor food quality; customers tired of eating the same meals; and, eating at home is still eating at home, with the accompanying food preparation and clean up chores. The company addresses these problems by delivering high quality food fresh and fast, providing customers a variety of meal choices from a diverse lineup of celebrity chefs, and requiring simple prep and easy clean up without sacrificing the fine dining experience.

Home Bistro offers a family of high quality, direct-to-consumer, ready-made, gourmet meals. Using the latest fresh food “skin-packing” technology, Home Bistro offers a virtual “Bistro Emporium” where consumers can cross select from a wide variety of siloed “bistros,” each with a dedicated section and unique visitor experience created by a renowned celebrity/executive chef. Meals delivered fresh can be eaten within 10 to 14 days or frozen for up to six months.

The company’s mission is to lead the next generation of heat-to-eat food delivery with unique and delicious cuisine and an experience that excites the market. Home Bistro’s advantage in the highly competitive meal delivery space is meal diversity – with the best celebrity chefs from around the world, offering a home-based fine dining experience through a selection of over 50 unique gourmet meals, as well as offering a developing selection of desserts and single-serving wine to perfectly complement the meal experience. In addition, the company uses only the highest quality ingredients in its meals and preserves their freshness by employing state-of-the-art vacuum skin packing.

In mid-2021, Home Bistro acquired southern-California based Model Meals, a lifestyle ready-to-eat meal prep service, which is Whole30 and Paleo approved, while then only serving three states. In September 2021, Home Bistro commenced shipping Model Meals to all 50 states and recently announced that it will launch a subscription-based service for Model Meals consisting of three meals per day (breakfast, lunch and dinner) for up to five days per week. The subscription service, expected to launch by May 2022, will initially target the Southern California market, where Model Meals maintains a food production and fulfillment facility and enjoys a strong customer base.

Brands and Products

Home Bistro’s leading online platform (www.homebistro.com) provides direct-to-consumer, heat-to-eat, celebrity chef-inspired gourmet meals. Offerings currently include inspirations developed by “Iron Chef” Cat Cora, two-time New York Times best-selling cookbook author and TV host Ayesha Curry, sports-tailgating focused creator of “Hungry Fan” Chef Diana Falk, “Master Chef” Claudia Sandoval, and “Top-Chef All-Star” Richard Blais. Soon-to-launch celebrity chefs on the Home Bistro platform include “Caterer to the Stars” Roblé Ali, “zero-waste cooking” celebrity chef Priyanka Naik, and CHOPPED champion Melanie Moss.

Home Bistro’s Model Meals lifestyle brand (www.modelmeals.com) is a Whole30 and Paleo approved, ready-to-eat meal prep service, offering a weekly rotating menu that is prepared by professional chefs, using only the highest quality ingredients available, sourced responsibly and locally, and delivered in sustainable, eco-friendly packaging.
Home Bistro has partnered with celebrity chef Melanie Moss to expand its dessert menu options. In keeping with its mission to deliver a complete gourmet culinary experience to discerning customers, Home Bistro beta-tested its first dessert – a delicious, sweet and salty caramel brownie. Based on the encouraging results, the company is moving forward to create a much more robust dessert menu.

Home Bistro has formally launched its wine offering initiative with In Good Taste Wines, a unique direct-to-consumer wine platform that empowers wine lovers to “discover the world, by the glass.” The company has worked diligently with the In Good Taste Wines team to develop a unique selection of elegant single-serving wines to pair with Home Bistro’s celebrity chef-inspired meals. The partnership with In Good Taste Wines provides Home Bistro with a low-cost, incremental source of revenue, which will assist the company in expanding its gross profit margin and lead it to faster profitability.

Market Outlook

Global revenue in the online food delivery sector was $136 billion in 2020 and forecast to grow steadily at a 7.5% CAGR through 2024 to a projected value of $182 billion.
In the U.S., the food delivery sector, which comprises both the restaurant-to-consumer segment and the platform-to-consumer segment where Home Bistro operates, is expected to surpass $32.3 billion in 2024. The company’s addressable market, the platform-to-consumer segment, is approximately 30% of the U.S. market and is projected to reach a value of $9.7 billion by 2024. This segment is expected to grow even faster than the sector as a whole as providers refine their focus on healthier meals, more convenient delivery and subscription options and more advanced meal processing technology.

Management Team

Zalmi Duchman is Chairman and CEO at Home Bistro. He was CEO and founder of The Fresh Diet online meal delivery service, which grew from a startup to over $30 million in annual revenue. He is a thought leader, investor and publisher of numerous articles in the food tech sector. He was named one of Forbes “America’s Most Promising CEOs Under 35,” and was named a Miami Herald “20 Under 40” entrepreneur in 2014.

Carlo Ricci is Director of Operations at Home Bistro. He was VP Operations for The Fresh Diet online meal delivery service, where he developed the culinary and R&D departments and established distribution centers in five states. He was also Operations Manager at Homemade Meals, where he developed and implemented inventory systems, established production facilities on both coasts and trained and managed personnel. He has a bachelor’s degree in data analytics from Miami Dade College.

Camille May is CFO at Home Bistro. She is a co-founder of Model Meals meal delivery service, where she has served as CFO since the company’s inception in 2015. She helped build the company from the ground up to more than $2 million in annual revenue. Prior to Model Meals, she worked as a financial analyst and broker in commercial real estate. She has a BBA in finance from the Leeds School of Business at the University of Colorado.

Danika Brysha is Chief Marketing Officer at Home Bistro. She co-founded Model Meals and was also a co-founder of the Self-Care Society. She is a former fashion model and founder of Danika Brysha Inc., a service specializing in modeling, coaching, speaking, events, media and influence. She is creator of the Brunch Series and a Whole30 certified coach. She is also host of the top-rated podcast “Light + Life Live” and is a lifestyle design expert. She earned a bachelor’s degree from the University of Colorado.

Home Bistro Inc. (OTC: HBIS), closed Wednesday's trading session at $0.29, even for the day, on 60 volume. The average volume for the last 3 months is 60 and the stock's 52-week low/high is $0.15/$1.98.

Recent News

Prime Harvest Inc.

The QualityStocks Daily Newsletter would like to spotlight Prime Harvest Inc.

Prime Harvest, a technology-focused, full-service cannabis company with horizontally diversified operations spanning various segments of the cannabis value chain, was featured in the Bell2Bell Podcast, a part of IBN’s (“InvestorBrandNetwork”) sustained effort to provide specialized content distribution via widespread syndication channels. Duane Alexander, CEO of Prime Harvest, joined the latest episode to discuss to discuss the company, its flagship brand and seasoned management team, recent milestones, and goals for the balance of 2022 and beyond. “Prime Harvest is a vertically integrated cannabis company. We’re based out of San Diego … and we’re positioned to expand into other markets in the State of California. We work in the licensing aspect [of the cannabis industry] and compliance. We also work in distribution, as well as branding and marketing,” Alexander said. “Jaxx is our flagship retail brand. We’ve currently positioned it in Ramona, San Diego County. We have another location that was recently licensed in the City of La Mesa, and we have three other locations in the pipeline for expansion this year.” To view the full press release, visit https://ibn.fm/xOndF

Prime Harvest Inc., based in San Diego, California, is a technology-focused, full-service cannabis company with horizontally diversified operations spanning various segments of the cannabis value chain, from licensing acquisition and compliance management to direct-to-consumer operations. The company is leveraging a long-term strategy of investing in the growth and scale of licensed assets anchored by the power of data-driven technology to expand its footprint throughout California.

Sustainability is key to Prime Harvest’s corporate vision. The company aims to ensure that the communities it serves capture their fair share of the fruits of the industry’s growth, including financial profit, employment opportunities, environmental enrichment and impactful innovation through R&D and education.

The company’s mission is to appeal to the ethos of the cannabis consumer by setting a new operational standard emphasizing accountability, sustainability and community. With this commitment, Prime Harvest continues to work toward positively affecting millions of lives through the creation of a world-class platform that caters to strengthening the commercial cannabis pipeline.

Jaxx Cannabis

Jaxx Cannabis is the flagship brand in Prime Harvest’s portfolio. Through Jaxx Cannabis, the company aims to use technology to facilitate a true customer-centric culture while enhancing the overall craft cannabis experience. Jaxx features an expertly curated selection of premium products from some of the most respected brands in the thriving California market.

Key values serving as the foundation of Jaxx Cannabis include:

  • Creating and nurturing a welcoming culture for all
  • Unlocking the true potential of customer value
  • Being innovative in uncovering new ways to grow both the company and the industry
  • Meeting the wants and needs of consumers to promote profitability
  • Remaining accountable for the results of its operations

It is these values that differentiate Prime Harvest and Jaxx Cannabis in the California cannabis sector.

Brand Partnerships

Prime Harvest works diligently to establish strong alliances with complementary brands that are in alignment with its culture and values. Through a combination of deliberate foresight and strategic action, the company seeks to grow existing cannabis brands and continuously discover new, high-potential performers that are primed for long-term success.

These partnerships enhance Prime Harvest’s efforts to transform the world’s cannabis access and bring its consumers high-quality products that are fair for both people and the planet.

Responsibility

Prime Harvest remains committed to the goal of creating a more sustainable environment, now and in the future. Concern for human beings and the environment can be observed in every facet of its operations, including its ongoing R&D activities dedicated to exploring methods of reducing and repurposing waste into composite materials and exploring the potential of the hemp plant for industrial and wellness contributions.

The company is a proud member of the Community Alliance Program, a foundation that seeks to make a difference in local communities by providing financial assistance for educational programs, housing homeless veterans, creating urban farms, and holding local arts initiatives for children and adults. The program also helps explore the natural healing attributes of medical cannabis through research, development, clinical trials, and advocating for the safe access of cannabis to those in need.

Market Overview

Ongoing changes in U.S. state government policies toward cannabis are expected to cause demand for legal marijuana to surge. In addition, the number of indications for which medical marijuana is prescribed continues to increase. These factors are expected to rapidly boost legal sales of cannabis products.

Legal sales across the U.S. hit a record of $17.5 billion in 2020, marking an increase of 46% over 2019, according to Forbes. This strong growth is expected to continue. According to a Grand View Research report, the global legal marijuana market is forecast to grow at a CAGR of 26.7 percent from 2021 to 2028.

California – Prime Harvest’s home state – has consistently led the pack in terms of U.S. cannabis sales. The Motley Fool pegged cannabis spending in the Golden State at $3.8 billion in 2020, more than doubling the second state on its list.

Leadership Team

The Prime Harvest team is composed of true experts in their respective fields focused on building a world-class organization capable of driving the cannabis industry and movement forward.

E. Duane Alexander is the company’s Founder and CEO. He brings to the team more than 25 years of real-world, hands-on cannabis retail, marketing and commercial operations experience. Mr. Alexander has championed 40+ cannabis license applications throughout the western U.S. to date.

John Wilczak is the COO of Prime Harvest. He has 30+ years of executive management, strategy development & configuration experience with GE, pharmaceutical and agriculture companies. Mr. Wilczak is a Brown & Columbia MBA with vast knowledge of technology driven intellectual properties.

Andrea Jenson is the Chief Financial Officer of Prime Harvest. As CFO, she is responsible for all the company’s financial functions, including accounting, corporate finance and investor relations. Her career spans more than 20 years of varied experience in financial management, business leadership and financial strategy.

John Kazanjian is the VP of Business Development of Prime Harvest. He has worked over 40 years in business operations, brand marketing, sales and investor/lender communications. Mr. Kazanjian earned his B.S. from Rutgers University and his MBA from Harvard University.

Johann Balbuena is the Chief Marketing Officer of Prime Harvest. She has more than six years of experience in California cannabis licensing acquisition and compliance management. Ms. Balbuena has led multimedia production and content marketing efforts for the likes of the Social Club TV app, The Emerald Cup, High Times, Weedmaps and Synergy.


Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agrochem and food/beverage industries, is partnering with Safer Medical of Montana (“SMM”) in an exclusive distribution agreement. SMM is a seasoned distributor of wellness products with a focus on veterans. The new partnership entails an agreement for production, distribution, commercial roll-out and finances for a novel, effectively water-soluble, nanoemulsified CBD spray for oral use. According to the announcement, SMM's roll-out and distribution plan anticipates revenues of $3 million or more over the first 12-months post-release of the product, with PBI receiving more than $1 million in revenues. This will be the first commercial product that utilizes Pressure BioSciences’ patented Ultra Shear Technology(TM) platform. “This first UST commercialization and partnering agreement with Captain Ackerson and Safer Medical of Montana is a pivotal transition moment in the history of PBI,” said Pressure BioSciences president and CEO Richard T. Schumacher in the press release. “We are expecting to announce significant additional agreements in the very near future, specifically in markets with an expected quick ramp to revenue, such as cosmetics, agrochem and nutraceuticals. We also believe that our co-leadership role in the Food Industry Consortium with partner The Ohio State University, whose mission is to introduce the UST platform to food and beverage companies worldwide, will soon result in additional revenue-generating agreements. We expect that the substantial revenue expected from these future agreements will accelerate balance sheet improvements and help finance PBI's operations, investments, growth and trajectory to profitability before the end of 2023." To view the full press release, visit https://ibn.fm/H3uqd

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions — all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Wednesday's trading session at $1.7, off by 2.8571%, on 15,001 volume. The average volume for the last 3 months is 15,001 and the stock's 52-week low/high is $1.51/$4.98.

Recent News

GreenBox POS (NASDAQ: GBOX)

The QualityStocks Daily Newsletter would like to spotlight GreenBox POS (NASDAQ: GBOX).

While cryptocurrencies are currently being battered on the market, the tech upon which they are based is finding new uses in the luxury brand segment. Players in this space have turned to blockchain as a way to fight back against counterfeiting, which costs different luxury brands billions in lost revenue as well as legal costs. The losses suffered by luxury brands are astronomical. For example, in 2017 alone, these brands reported a total of $98 billion in lost sales. The cost of counterfeits isn’t just restricted to the monetary aspect — even the reputation of the brand suffers when a customer who thought they had bought the genuine item is disappointed by not receiving value from the product. In short, while cryptocurrencies are currently going through a rough patch, blockchain technology is alive and well. Entities such as GreenBox POS (NASDAQ: GBOX) will keep pushing the envelope of their usefulness until this technology penetrates every aspect of human endeavor.

GreenBox POS (NASDAQ: GBOX) is an emerging financial technology company leveraging proprietary security and token technology to build customized payment solutions for business. The company’s mission is to build compliant, cutting-edge blockchain ledger tokenized solutions for the diverse, evolving and dynamic global market.

GreenBox applications enable an end-to-end suite of turnkey financial products which offer improved fraud detection and better handling efficiency of large-scale commercial payment processing volumes for its merchant clients globally. The company’s proprietary blockchain and smart contract token technologies create seamless payment processing using digital encryption keys.

GreenBox is a unified platform providing scalability for businesses to accept payments, transact, send, settle and convert in a single versatile ecosystem. GreenBox operates a private and proprietary blockchain-based payment platform that offers distinct advantages when compared to traditional payment technologies, including greater security and data privacy, as well as enhanced identity theft protection and quick settlement.

As the settlement engine for financial transactions, GreenBox’s blockchain technology is a distributed ledger that uses digitally encrypted keys to verify, secure and record details of each transaction conducted within GreenBox’s private ecosystem. The speed and security of the platform allows GreenBox to log immense volumes of immutable transactional records in real time for Tier-1 partners around the world.

In November 2021, GreenBox announced the closing of a previously announced $100 million convertible note financing. The company plans to use proceeds for acquisitions, a planned stablecoin spin-off, and additional working capital toward the company’s future growth. The initial conversion price equals a more than 80 percent premium to the market price of the company’s common stock on October 29, 2021, and values the enterprise at more than $700 million upon conversion.

Brands & Solutions

The company offers multiple solutions and brands under the GreenBox label. The other brands that are nested under the GreenBox POS label include coyni, ChargeSavvy, QuickCard, Transact Europe [didn’t yet close] and Northeast Merchant Systems. Each of these brands play a large role in allowing GreenBox to accel in customizing payment solutions across different verticals and industries.

Payment Solutions

The GreenBox platform offers blockchain secure, robust payment processing solutions for both individual consumers and businesses. The company combines the power and security of blockchain with bank-level tools necessary to both settle transactions and monitor cash flows. Customers can transfer cryptocurrencies like USDC, Ethereum or Bitcoin from external decentralized crypto wallets to their GreenBox wallets. They can also exchange those tokens from their GreenBox wallets to any supported coin. Customers can easily offload in USDC to a debit card or a multitude of gift cards.

White Label Solutions

The company’s white label platform allows it to partner with firms seeking blockchain-based tools to manage merchant relationships. White label partners can monitor cash flows, as well as run reports on merchant transactions, chargebacks, agent and affiliate commissions and more. Partners can access the platform through their partner portal to manage business relationships with full visibility. The platform’s cutting-edge technology saves partners time and simplifies their payment processing. It ensures compliance with automated Know Your Customer and Know Your Bank services and allows customers to set up automated payouts.

coyni Stablecoin

The company is planning soon to launch its own stablecoin, coyni (CYN). coyni is equivalent to the value of the U.S. dollar on a one-to-one ratio. Stablecoin allows for instantaneous transactions with blockchain security just like other cryptocurrency tokens, but without the price volatility of traditional cryptocurrencies. The CYN token is expected to make possible features like digital dollar accounts, cross border payments, international payment processing and other payment solutions. As a smart contract technology, coyni will offer instant settlement using the GreenBox blockchain ledger in any location and currency – crypto or fiat – all at lower fees and in a tokenized secure ecosystem.

Market Overview

A Mordor Intelligence report put the transaction value of the global digital payments market at $5.44 trillion in 2020 and projects the market to be worth $11.29 trillion by 2026. That represents a CAGR of 11.21 percent during the period of 2021-2026.

The report notes that the global COVID-19 pandemic and its impact on e-commerce is likely to encourage strengthened international cooperation and further development of policies for online purchasing and supply. The report states, “The pandemic has made it clear that e-commerce can be an important tool/solution, especially considering the fact that e-commerce sales can support small and medium businesses that form the backbone for certain economies. This is expected to substantially spur the growth of digital payment methods across various economies.”

According to Mordor, other drivers of the growth trend in digital payments include:

  • Greater convenience, favorable government policies and evolving consumer behavior worldwide
  • Rapid rise in smartphone penetration throughout emerging economies
  • Introduction of mobile wallets across the world
  • Widespread adoption of retail digital payment services across the vast population of China, serving as a kind of test case for other countries

Management Team

Ben Errez, Chairman of the Board of Directors

Ben Errez’s past positions have included positions at large companies like Microsoft and Intel. He has brought this expertise to lead GreenBox into the forefront of the blockchain-based financial software, services, and hardware market.

Mr. Errez was one of the early managers of Microsoft in 1991. From 1991 to 2004, he served as Software Development Lead for the Microsoft International Office Group. He led the International Microsoft Office Components team (Word, Excel, PowerPoint) in design, engineering, development, and successful deployment. He also served as Executive Representative of Microsoft Office and was a founding member of the Microsoft Trustworthy Computing Team both within the company and internationally. Mr. Errez co-authored the first Microsoft Trustworthy Computing Paper on Reliability. At Microsoft, he was responsible for the development of the first Microsoft software translation Software Development Kit (“SDK”) in Hebrew, Arabic, Thai, and Simplified Chinese, as well as the development of the first bidirectional extensions to Rich Text Format (“RTF”) file format and all bidirectional extensions in text converters for Microsoft Office. He also contributed to the development of the international extensions to the Unicode standard to include bidirectional requirements under the World Wide Web Consortium (“W3C”).

In 2004, Mr. Errez transitioned into the world of consulting, where he held the position of Principal Consultant from founding to the present date, through which he advises clients in the South Pacific region with market capitalizations ranging from $50 million to $150 million on commerce, security, reliability, and privacy.

In 2017, immediately before partnering with Fredi Nisan to launch GreenBox, Mr. Errez was asked to take over the Microsoft Alumni Network for the Southern California region as a regional director. Mr. Errez has been a principal of GreenBox since its inception in 2017.

Fredi Nisan, Chief Executive Officer

Fredi Nisan’s career in technology began during his years of service in the Israeli Defense Forces, where he served as IT Manager for all of Israel’s Northern Bases. After serving in the military, Mr. Nisan opened and operated a computer hardware store before becoming the Inventory Operations Manager for Zicon Israel in 2005, a hardware and software producer. At Zicon, he supervised inventory operations, worked on quality controls for motherboards and chips, and educated customers on software and hardware product functionality. Subsequently, Mr. Nisan moved to the United States, where he worked for One Coach in San Diego, California, as a business coach. One Coach specializes in customized growth solutions for small business owners, including the latest strategies for sales, internet marketing, branding, and ROI. Mr. Nisan was consistently ranked as the top salesperson for small business coaching while working with One Coach.

In 2010, Mr. Nisan launched Brava POS, where he served as President until 2015. Brava POS provided point of sale (“POS”) systems for specialty retail companies. Mr. Nisan developed software to provide clients with solutions for issues ranging from inventory management to payroll to processing high volume transactions in the form of a cloud-based POS system. This system had the capability to manage multiple stores with centralized inventory and process sales without an internet connection, and offered a secure login for each employee, as well as including advanced inventory management and reporting, plus powerful functionality for its end users.

In 2016, Mr. Nisan founded Firmness, LLC. Through Firmness, he created “QuickCitizen,” a software program that simplifies the onboarding process for new clients of law firms specializing in immigration issues. The QuickCitizen software significantly reduced law firms onboarding processing time from more than three hours to approximately 15 minutes. Mr. Nisan has been a principal of GreenBox since its August 2017 inception. In January 2018, Firmness sold QuickCitizen to GreenBox.

Jacquline B. Reynolds, Chief Marketing Officer

Jacqueline B. Reynolds is the company’s Chief Marketing Officer. She served most recently as vice president of marketing for Sprouts Farmers Market. She has built her reputation as a world-class global marketer, working with Coca-Cola, McDonald’s, Verizon, Walmart, L’Oréal, Xbox, 7-Eleven and many other Fortune 500 brands. She has managed award-winning marketing programs with partners such as the NFL, Super Bowl LIV, the Olympics, the FIFA World Cup, Sony Pictures, Universal Music and others.

GreenBox POS (NASDAQ: GBOX), closed Wednesday's trading session at $1.05, off by 10.2564%, on 471,994 volume. The average volume for the last 3 months is 470,259 and the stock's 52-week low/high is $1.02/$13.22.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

New Jersey’s senate president recently filed a bill that would legalize the home cultivation, possession and gifting of psilocybin or magic mushrooms to adults aged 21 and older. The psychedelic reform bill contains provisions that would grant the psychedelics market more freedoms than the cannabis market. Last February, New Jersey Governor Phil Murphy signed a bill that reclassified the possession of psilocybin mushrooms from a third-degree crime with a penalty of three to five years in jail and up to $15,000 in fines to a disorderly persons offense with a maximum fine of $1,000, up to six months’ jail time, or both. The Psilocybin Behavioral Health Access and Services Act seeks to completely decriminalize the possession, home growth and sharing of psilocybin mushrooms. Furthermore, it would allow for the creation of licensed establishments that offer supervised psilocybin services. The bill was introduced by New Jersey Senate President Nicholas Scutari, a long-time proponent of cannabis reform in the state. These attempts to reform psychedelic policies in different states are coming at a time when major companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) have made significant strides in their push to develop treatments from different psychedelic compounds.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Wednesday's trading session at $0.5593, off by 3.2353%, on 604,305 volume. The average volume for the last 3 months is 600,665 and the stock's 52-week low/high is $0.3903/$3.38.

Recent News

Odyssey Group International Inc. (OTC: ODYY)

The QualityStocks Daily Newsletter would like to spotlight Odyssey Group International Inc. (OTC: ODYY).

  • Odyssey Health is a medical company focused on developing medical products for conditions with unmet needs, one of which is concussion
  • Currently, concussions do not have an FDA-approved treatment
  • Soldiers form a significant population of people who frequently experience multiple concussions throughout their career
  • Concussion has only recently received greater attention as different parties seek to understand the condition and possible treatments
  • Odyssey is at the forefront of this pursuit for treatment and has developed the PRV-002 drug candidate that it intends to use on the military as part of a Phase II clinical trial
  • The company announced the formation of a Military Advisory Board to help in this journey

According to a study by the Business Development Bank of Canada (“BDC”), 86% of businesses with an advisory board say it has had a substantial impact on their operations. In addition, the study showed that companies with an advisory board witnessed 24% higher annual sales and 18% higher productivity than businesses without one (https://ibn.fm/K437C). Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., a company focused on developing unique, life-saving medical products, today announced positive safety findings from cohort II of its phase I clinical trial. According to the update, the trial involves administering PRV-002, Odyssey’s novel drug to treat concussion, to healthy human subjects. Cohort II data indicates that the drug was safe and well-tolerated. “PRV-002 continues to be well-tolerated as we increase the intranasal dose levels,” said Michael Redmond, CEO of Odyssey Health. “We look forward to completing phase I clinical trials and moving into a phase II/III to determine the efficacy of PRV-002 for concussed patients. I believe that intranasal brain-targeting will be the key to its success. We are currently in discussions with military training sites for our phase II/III clinical trials.” To view the full press release, visit https://ibn.fm/EoG2w.

Odyssey Group International Inc. (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care.

The company’s portfolio of product technologies is diverse, featuring four unique medical products in development. Odyssey’s goal is to deliver superior products with enhanced clinical utility and market potential, thereby yielding a high rate of return for its shareholders and partners. It is guided by a senior management team with significant experience relating to refining technologies, building commercial systems and forging strategic partnerships.

Product Portfolio

Pharmaceuticals

Odyssey has two pharmaceutical products in development:

  • PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. Importantly, the first-in-class novel neurosteroid demonstrated no drug-related toxicity in these trials.
    • PRV-002 is currently being evaluated in a phase I clinical trial for the treatment of concussion, with phase II trials planned for launch in Fall 2022. Odyssey has also highlighted the potential of PRV-002 for additional indications such as Alzheimer’s disease, Parkinson’s disease, ALS and chromic traumatic encephalopathy (CTE).
  • PRV-001 is a novel compound intended to treat Niemann-Pick disease, a rare neurodegenerative-lysosomal storage disorder that affects an estimated 1 in 150,000 individuals in the U.S., demonstrating a 5x higher incidence in Middle Eastern populations.
    • Odyssey expects to receive Orphan Drug designation from the FDA for PRV-001, which would accelerate its pathway to FDA approval and provide seven years of market exclusivity.

Medical Devices

Odyssey is also developing two medical device candidates:

  • CardioMap® is intended to provide early, non-invasive testing for heart disease. The system offers a number of potential advantages over traditional EKGs, including requiring less training to operate, offering heightened sensitivity and coming in a small and portable form factor. CardioMap is being developed for a 510(k) regulatory pathway, which requires a study to demonstrate equivalence to legacy EKG offerings.
    • When approved, CardioMap is expected to be the only device in its class that has a predictive value, illustrating ‘grey’ areas where deterioration has begun but not yet led to pathology. Odyssey expects this feature to provide a powerful incentive for doctors to use the CardioMap device in end markets such as hospitals, doctors’ offices, rehabilitation centers and sports medicine practices.
  • Save-A-Life (SAL) is a patented, single-action, instantaneous, handheld, mechanical anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds, all without harm to the victim. The device is currently in development, with a proof of concept established.
    • Odyssey believes that, once FDA-approved, its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally. Its low-cost manufacturing and convenient portable design give SAL a competitive edge over competing devices utilizing cumbersome masks.

Market Opportunities

Odyssey’s varied development pipeline positions it to address a number of sizable market opportunities with significant unmet medical need. Concussions alone currently account for medical costs of roughly $10-15 billion annually in the U.S., despite the lack of a currently approved FDA drug treatment. This need is particularly apparent in the military and sports industry, where the likelihood of athlete head-injury recurrence is estimated at 75%.

It is for this reason that, in March 2021, Odyssey announced the formation of a sports advisory board featuring well-known athletes supporting the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Members of Odyssey’s sports advisory board include NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach.

With its CardioMap platform, Odyssey is targeting the global cardiac monitoring market, which was valued at $28 billion in 2021 by Insight Partners and forecast to reach $43 billion by 2028.

Save-A-Life targets a similarly underserved market. Choking is the fourth-leading cause of death in children, and approximately 5,000 choking deaths occur each year in the U.S. While 95% of these deaths result from in-home incidents, current choking rescue devices fail to address in-home applications.

Management Team

Joseph Michael Redmond is the President, CEO and Chairman of Odyssey. He has over 30 years of commercial experience in medical device companies, previously serving as CEO of Parallax Health Sciences Inc., V.P. of Business Development for DxTech Inc. and V.P. of Sales and Marketing for Bioject Medical Technologies Inc. While at Bioject, Mr. Redmond helped raise over $15 million in capital, entered into several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10 million to over $400 million. He started his career at Abbott Labs and holds a B.A. from Denison University.

Christine M. Farrell is the company’s CFO and Secretary. Prior to joining Odyssey, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc. She also held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. in Accounting from the University of Washington and an M.B.A. from Willamette University.

Dr. Jacob W. Vanlandingham is Odyssey’s Head of Drug Development. Dr. Vanlandingham holds a Ph.D. in neuroscience with a molecular biology focus. He is a member of the Society for Neuroscience, American Society for Nutritional Sciences, National Neurotrauma Society, Faculty for Undergraduate Research in Neuroscience and the International Association of Medical Science Educators.

Odyssey Group International Inc. (OTC: ODYY), closed Wednesday's trading session at $0.2475, off by 1%, on 39,775 volume. The average volume for the last 3 months is 39,775 and the stock's 52-week low/high is $0.11/$0.7497.

Recent News

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF)

The QualityStocks Daily Newsletter would like to spotlight Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF).

  • In 2021, Eat Well acquired Belle Pulses Ltd. Sapientia Technologies Inc. and a 51% stake at Amara Organic Foods
  • These acquisitions saw a 1,082% growth in the company’s assets for the 2021 financial year and a 320% revenue growth for Amara
  • With the plant-based foods market projected to be valued at $162 billion by 2030, Eat Well expects to capitalize on this growth through M&As and strategic partnerships with key players in the industry
  • Eat Well is confident that with the foundation laid down so far, it is poised to achieve $100 million in revenue for 2022

At the close of the 2021 calendar year, Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) (FRA: 6BC0) was regarded as “One to Watch.”  This mainly stemmed from its aggressive market expansion plans, vertical integration, and the bolstering of its leadership (https://ibn.fm/tFGDP).

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF), headquartered in Vancouver, British Columbia, is a publicly traded vertically integrated plant-based foods company combining the best of agribusiness, foodtech, and CPG brands to supply the world with innovative, delicious, and better-for-you foods. The company supplies Beyond Meat, Ingredion, Nestle, General Mills and more. It is on track to generate $60 million in revenue for 2021 and is projecting $100 million in revenue for 2022.

Eat Well’s management team has an extensive record of sourcing, financing and building successful companies across a broad range of industries and maintains a current investment mandate on the health and wellness industry. The team has financed and invested in early-stage venture companies for more than 25 years, resulting in the ability to construct a portfolio of opportunistic investments intended to generate superior risk-adjusted returns. Eat Well’s strategic advisory board includes pioneers in the plant-based foods industry, including HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, and Jeff Dunn, CEO of Bolthouse Farms who previously held senior leadership positions at both Campbell Soup Company and The Coca Cola Company.

The company’s plant-based investment thesis is centered on growing its seed-to-market operations, which include raw ingredients, processing, pulse fractionation, unique IP and premium consumer packaged goods (CPG). Eat Well Group is building a unique ecosystem that can supply these essential cornerstone needs for society. The company has plant-based foods and nutrition experts specializing in the latest science and original thinking for what consumers want most – high quality and affordability in healthy, clean and simple products.

Eat Well focuses on intellectual property, product portfolio development and long-term value creation for stakeholders in a rapidly expanding industry. As an emergent sector globally, plant-based foods represent a double-digit annual growth category, with more than 35% of the world’s supply of pulse proteins coming from Canada.

Portfolio

On July 31, 2021, Eat Well Group acquired Belle Pulses Ltd., one of the top pulse processors in Canada. Belle Pulses has been operating for over 40 years and had over $60 million in sales in 2020. The company counts a broad range of customers in over 35 countries, including global strategic food companies and major ingredient distributors. Currently, Belle produces nearly 100,000 tons of fully traceable seed and product, yielding over 26,000 tons of pure plant protein.

Eat Well also owns 100% of Sapientia Technology Inc. Led by Dr. Eugenio Bortone – one of the world’s preeminent food scientists and extrusion processing experts and the inventor of Frito-Lay’s Twisted Cheetos – Sapientia has filed four patents around the “protein curl” and crispy-puff-style snack. By focusing on texture and crunch, Sapientia’s patents solve one of the major problems that large scale snack food companies have struggled with for years – how to offer appealing texture and flavor in a guilt-free, not fried, natural and healthy alternative to the majority of snack food products available today.

Eat Well owns a 51% share of Amara Organic Foods, with an option to acquire additional ownership up to 80 percent. Amara, one of the fastest-growing baby food brands in America, is a food technology company that uses science and proprietary IP that locks in taste and texture to make healthy, organic, non-GMO, plant-based, convenient baby and children’s food possible for modern-day families. From baby food to toddler food and beyond, Amara is driven by the belief that setting kids on the right path from a young age will help them live better, feel better and think better for the rest of their lives. Amara’s revenues have grown by more than 400% since January 2021, and the brand’s success has drawn media coverage from business news outlets including Forbes and TechCrunch.

Market Outlook

According to an August 2021 report from Bloomberg Intelligence, the plant-based foods market is expected to experience explosive growth, comprising up to 7.7% of the global protein market by 2030 at a value of over $162 billion, up from $29.4 billion in 2020. Bloomberg notes that plant-based alternatives are here to stay, and that consumption will grow rapidly. Plant-based food sales in 2020 grew twice as fast as overall food sales, according to Polaris Market Research.

Pulse proteins (fava, yellow pea, etc.) are a foundational ingredient to most plant-based foods due to their high protein content and their readily available, affordable supply.

Many analysts view the food tech market as similar to the early days of the Internet in that plant-based foods represent a worldwide secular trend of steady growth and potential that will revolutionize the way society functions and people experience nutrition.

The sector continues to experience significant M&A transactions. Recently, Sol Cuisine was acquired by PlantPlus Foods LLC, a major South American protein producer, in an all-cash transaction valued at approximately $126 million, or 6x revenue.

Management Team

Marc Aneed is President and Director of Eat Well Group. His 20-year career in CPG started at The Quaker Oats Company/PepsiCo, where he worked on iconic brands like Gatorade. He previously was at Glanbia PLC, a global nutrition company, where he led Amazing Grass, a leading plant nutrition and supplement company with over $100 million in retail sales. He also led Glanbia’s Sports Nutrition brands in North America with over $750 million in retail sales. Mr. Aneed has launched dozens of successful consumer products, driving over $1 billion in collective retail sales.

Mark Coles is the company’s Chief Investment Officer. He is a veteran CPG senior executive specializing in the plant-based foods sector. For the past decade, Mr. Coles has spearheaded global plant-based start-up initiatives, culminating in a 2020 acquisition by an international New York Stock Exchange-listed food ingredient company. He has over 25 years of experience in CPG-focused strategy, mergers and acquisitions and project financing.

Patrick Dunn is Eat Well Group’s Vice President, Finance. He is the founding partner of Dunn, Pariser & Peyrot and has a track record of building highly successful agribusinesses throughout North America and other international markets. As a testimony to his business portfolio work, Mr. Dunn and his firm have won multiple industry awards for accounting, finance and business management.

Barry Didato is the company’s Vice President, Strategy. He is focused on the development of strategic revenue channels, sales partnerships, and international distribution for Eat Well Group. Mr. Didato brings extensive strategic sales capabilities and an extensive network of contacts in the industry to the company. Prior to joining Eat Well Group, he served for over 18 years as a senior advisor for several ultra-high net worth family offices and numerous innovative wellness, nutrition, medical, and food businesses.

Strategic Advisory Board

HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, is a firm supporter of clean energy and the humane treatment of animals. He is also a vocal supporter of the private sector in the Middle East. A member of the Saudi Arabian Royal Family, Prince Khaled was born in Stanford and spent his youth in Riyadh under the mentorship of his father, philanthropist HRH Prince Alwaleed bin Talal Al Saud, Chairman of Kingdom Holding Company. He is also the Founding Chairman of KBW Investments and serves across several boards. He invests in an array of successful but diverse global businesses – from promising technology startups to established companies. Today, with holdings on three continents, Prince Khaled stands at the gateway between the Middle East’s evolving economies and the Western world. Consistently, Prince Khaled’s focus is on ventures and ideas at the intersection of innovation and economic growth.

Jeff Dunn has over 30 years of experience in agriculture and packaged food, including senior leadership positions with Bolthouse Farms, Campbell Soup Company and The Coca Cola Company, among others. He is an Operating Partner at Butterfly and focuses primarily on the agriculture & aquaculture and food & beverage product sectors. Prior to joining Butterfly, Mr. Dunn was the President of the Campbell Fresh division of Campbell Soup Company from 2015 to 2016, where he was in charge of building Campbell’s scale and accelerating its growth in the rapidly expanding packaged fresh segments and categories across the retail perimeter.

Eat Well Investment Group Inc. (OTC: EWGFF), closed Wednesday's trading session at $0.18, off by 9.045%, on 20,500 volume. The average volume for the last 3 months is 20,500 and the stock's 52-week low/high is $0.15/$1.00.

Recent News

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF)

The QualityStocks Daily Newsletter would like to spotlight LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF).

LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), a company focused on developing institution-grade payment infrastructure, liquidity and solutions for the Lightning Network (“LN”), has been scaling its capacity on the LN to drive awareness and growth. “The company’s flagship platform-as-a-service (‘PaaS’) offering, https://lqwd.tech/, was released in November 2021 in addition to the first company node on the Lightning Network – US-West. As the company’s longest operating node, the US-West node’s capacity is the highest – 5.73377252 BTC, which translates to 573,377,252 Satoshi/ US$121,051.86. Currently, 104 channels and 103 connected nodes are active on the network to the company’s Lightning Network node. Over the last 30 days, the US-West node has experienced growth overall, an increase of .250353 BTC (+4.57%) with an average channel capacity on the node of .055 BTC (US$1,162.01),” a recent article reads. “Including the US-West, the current node count operated by LQwD on the Lightning Network is 17. These nodes facilitate transactions in destinations worldwide, including Japan, England, Canada, France, Italy, Indonesia, Bahrain, South Africa, South Korea, Sweden, Singapore, Hong Kong, Brazil, Germany, India, and Ireland.” To view the full article, visit https://ccw.fm/NRc0v

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) is a financial technology company focused on creating enterprise-grade infrastructure to drive bitcoin adoption.

LQwD FinTech’s mission is to develop institutional-grade services that support the Lightning Network and drive improved functionality, transaction capability, user adoption and utility, and scaling of bitcoin. LQwD is also securing a substantial position in bitcoin as an operating asset and will use its holdings to establish nodes and payment channels on the Lightning Network.

The Lightning Network is a second-layer protocol, sitting above the bitcoin blockchain, intended to facilitate faster micro-transactions and lower fees on bitcoin transactions, thus allowing mass adoption of bitcoin.

LQwD expects the Lightning Network to eclipse the patchwork of legacy financial networks that are used to move value today. The company’s software will make migration from legacy networks onto the Lightning Network easy and seamless. By onboarding more financial service providers, LQwD intends to grow the value of the Lightning Network.

The company, formerly known as Interlapse Technologies Corp., is harnessing new payment rails built on top of the bitcoin blockchain that are capable of beyond visa-level transaction volumes and backed by bitcoin, the strongest and most well-known cryptocurrency. These new rails, enabled by the Bitcoin Lightning Network, open a vast opportunity and market segment for digital payments and financial services on a global scale. LQwD aims to leverage its position as a public company to enhance trust in its products and services, and leverage its shares as currency for acquisitions, roll-up and growth, as well as to attract and retain top industry talent.

Product

The Lightning Network is a solution to massively scale the use of bitcoin for microtransactions globally, dramatically improving upon fees, as well as providing instant settlement times. The Lightning Network has experienced explosive growth and is expected to continue with the trend as usage increases. Well-known companies, such as Twitter and Square, have expressed their enthusiasm to incorporate Lightning Network into their platforms. The Lightning Network is scalable, global, open, inclusive, permissionless and decentralized. It is made up of nodes connected via payment channels, and enables off-chain, instantaneous and cheap payments at scale.

Upon launch of LQwD’s Lightning Network platform-as-a-service, users will be able to leverage the Lightning Network infrastructure to send payments instantly, securely and inexpensively anywhere in the world. Companies and service providers will be able to conduct Lightning Network transactions in bitcoin by integrating LQwD’s infrastructure with their business or web property. Connected businesses will be able to easily deploy, monitor and manage LQwD’s Lightning Network nodes with no or low-level technical knowledge required. The company fully expects Lightning Network to be a force for global change and to become the monetary exchange network of the future.

The Lightning Network, which is already built, functioning and growing, will advance bitcoin from a store-of-value to a global monetary network through payment utility. The company expects the Lightning Network will propel the growing number of active blockchain wallets to new heights, by increasing bitcoin’s scalability and lowering its fees for users. For coming generations, everything from wealth to experiences will be acquired and transacted virtually, and LQwD sees the Lightning Network as an enabling technology that can bring bitcoin to hundreds of millions of new users across the globe.

Market Outlook

Forbes in August 2021 noted that “private investors are funding companies that are building the infrastructure that will support future growth of crypto and digital assets,” and called public companies building cryptocurrency infrastructure “the hottest part of the crypto market.” While the first wave of investor interest in crypto firms was directed at companies catering to retail investors, investors have now shifted their attention to infrastructure builders, like LQwD FinTech. Forbes did not put an estimated value on the crypto infrastructure market but pointed out that large-scale adoption of cryptocurrencies will only happen when infrastructure is in place to support it. The larger digital payments market, of which crypto payments are a small fraction, is growing at more than 14 percent annually and is forecast to hit $154 billion by 2025.

Management Team

Shone Anstey is co-founder, chairman and CEO at LQwD FinTech. He has 20 years of experience in building complex technologies and has acted as technology lead for an industrial bitcoin mine and bitcoin mining pool. He is a Certified Cryptocurrency Investigator, and an advisor to the British Columbia Securities Commission. He is also co-founder of BIGG Digital Assets (OTCQX: BBKCF) and took that company public in 2017.

Barry MacNeil is CFO at LQwD FinTech. He is a member of the Chartered Professional Accountants of British Columbia and has more than 30 years of management and accounting experience with public companies and in private practice. His previous positions include director of both public companies and nonprofits, as well as Chief Financial Officer and Corporate Controller.

Albert Szmigielski is co-founder and CTO at LQwD FinTech. He was formerly the Head of Research and Chief Blockchain Engineer at Blockchain Intelligence Group and VP Research at CipherTrace. He holds a B.Sc. in Computing Science from Simon Fraser University, and a Master of Science in Digital Currencies and Blockchain Technologies from the University of Nicosia, Cyprus.

LQwD FinTech Corp. (LQWDF), closed Wednesday's trading session at $0.0882, off by 10.999%, on 242,300 volume. The average volume for the last 3 months is 242,300 and the stock's 52-week low/high is $0.0754/$0.672.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.